Submit
Search
Submit
Menu

  • Information

  • References

  • Contents

  • [1]Weiderpass E, Labrà che F: Malignant tumors of the female reproductive system. Safety and health at work 3(3), 166-180 (2012)

  • [2]Hedenfalk I, Duggan D, Chen Y, Radmacher M, Bittner M, Simon R, Meltzer P, Gusterson B, Esteller M, Raffeld M: Gene-expression profiles in hereditary breast cancer. New Engl J Med 344(8), 539-548 (2001).

  • [3]Bruchim I, Sarfstein R, Reiss A, Flescher E, Werner H: IGF1R tyrosine kinase inhibitor enhances the cytotoxic effect of methyl jasmonate in endometrial cancer. Cancer lett 352(2), 214-219 (2014)

  • [4]Waggoner SE: Cervical cancer. The Lancet 361(9376), 2217-2225 (2003)

  • [5]Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 75(3), 495-505 (1993)

  • [6]Scheffner M, Werness BA, Huibregtse JM, Levine AJ, Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63(6), 1129-1136 (1990)

  • [7]Werness BA, Levine AJ, Howley PM: Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248(4951), 76-79 (1990)

  • [8]Vaughan S, Coward JI, Bast RC, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D: Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11(10), 719-725 (2011)

  • [9]Pothuri B: BRCA1-and BRCA2-related mutations: therapeutic implications in ovarian cancer. Annals of oncol 24(suppl 8):viii22-viii27 (2013)

  • [10]Fung-Kee-Fung M, Oliver T, Elit L, Hirte HW, Bryson P: Optimal chemotherapy treatment for women with recurrent ovarian cancer. Current Oncol 14(5) (2007)

  • [11]Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, Gebski V, Heywood M, Vasey PA, Volgger B, Vergote I, Pignata S, Ferrero A: Pegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol 28(20), 3323-3329 (2010)

  • [12]Markman M, Liu PY, Moon J, Monk BJ, Copeland L, Wilczynski S, Alberts D: Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m 2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecol oncol 114(2), 195-198 (2009)

  • [13]Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott C, Meier W, Shapira-Frommer R, Safra T: Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New Engl J Med 366(15), 1382-1392 (2012)

  • [14]de Murcia G, Menissier de Murcia J: Poly(ADP-ribose) polymerase: a molecular nick-sensor. Trends Biochem Sci 19(4), 172-176 (1994)

  • [15]He JX, Yang CH, Miao ZH: Poly(ADP-ribose) polymerase inhibitors as promising cancer therapeutics. Acta Pharmacol Sin 31(9), 1172-1180 (2010)

  • [16]Drew Y, Plummer R: PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications. Drug Resist Updat 12(6), 153-156 (2009)

  • [17]Ossovskaya V, Koo IC, Kaldjian EP, Alvares C, Sherman BM: Upregulation of Poly (ADP-Ribose) Polymerase-1 (PARP1) in Triple-Negative Breast Cancer and Other Primary Human Tumor Types. Genes Cancer 1(8), 812-821 (2015)

  • [18]Li D, Bi F-F, Chen N-N, Cao J-M, Sun W-P, Zhou Y-M, Li C-Y, Yang Q: A novel crosstalk between BRCA1 and poly (ADP-ribose) polymerase 1 in breast cancer. Cell Cycle 13(21), 3442-3449 (2014)

  • [19]Green AR, Caracappa D, Benhasouna AA, Alshareeda A, Nolan CC, Macmillan RD, Madhusudan S, Ellis IO, Rakha EA: Biological and clinical significance of PARP1 protein expression in breast cancer. Breast Cancer Res Treat 149(2), 353-362 (2015)

  • [20]Stanley J, Klepczyk L, Keene K, Wei S, Li Y, Forero A, Grizzle W, Wielgos M, Brazelton J, LoBuglio AF, Yang ES: PARP1 and phospho-p65 protein expression is increased in human HER2-positive breast cancers. Breast Cancer Res Treat 150(3), 569-579 (2015)

  • [21]Krukenberg KA, Jiang R, Steen JA, Mitchison TJ: Basal activity of a PARP1-NuA4 complex varies dramatically across cancer cell lines. Cell Rep 8(6), 1808-1818 (2014)

  • [22]Lee Y-H, Liu X, Qiu F, O Connor TR, Yen Y, Ann DK: HP1β is a biomarker for breast cancer prognosis and PARP inhibitor therapy. PLoS One 10(3), e0121207 (2015)

  • [23]Bryant HE, Petermann E, Schultz N, Jemth AS, Loseva O, Issaeva N, Johansson F, Fernandez S, McGlynn P, Helleday T: PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination. EMBO J 28(17), 2601-2615 (2009)

  • [24]Schlacher K, Christ N, Siaud N, Egashira A, Wu H, Jasin M: Double-strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by MRE11. Cell 145(4), 529-542 (2011)

  • [25]Somyajit K, Saxena S, Babu S, Mishra A, Nagaraju G: Mammalian RAD51 paralogs protect nascent DNA at stalled forks and mediate replication restart. Nucleic Acids Res 43(20), 9835-9855 (2015)

  • [26]Ghabreau L, Roux JP, Frappart PO, Mathevet P, Patricot LM, Mokni M, Korbi S, Wang ZQ, Tong WM, Frappart L: Poly (ADP-ribose) polymerase 1, a novel partner of progesterone receptors in endometrial cancer and its precursors. Intl J Cancer 109(3), 317-321 (2004)

  • [27]Shen WH, Balajee AS, Wang J, Wu H, Eng C, Pandolfi PP, Yin Y: Essential role for nuclear PTEN in maintaining chromosomal integrity. Cell 128(1), 157-170 (2007)

  • [28]Dedes KJ, Wetterskog D, Mendes-Pereira AM, Natrajan R, Lambros MB, Geyer FC, Vatcheva R, Savage K, Mackay A, Lord CJ: PTEN deficiency in endometrioid endometrial adenocarcinomas predicts sensitivity to PARP inhibitors. Science transl med 2(53), 53ra75 (2010)

  • [29]Kim JJ, Kurita T, Bulun SE: Progesterone action in endometrial cancer, endometriosis, uterine fibroids, and breast cancer. Endocrine rev 34(1), 130-162 (2013)

  • [30]Hassumi-Fukasawa MK, Miranda-Camargo FA, Zanetti BR, Galano DF, Ribeiro-Silva A, Soares EG: Expression of BAG-1 and PARP-1 in precursor lesions and invasive cervical cancer associated with human papillomavirus (HPV). Pathol & Oncol Res 18(4), 929-937 (2012)

  • [31]Roszak A, Lianeri M, Sowiska A, Jagodziski PP: Involvement of PARP-1 Val762Ala polymorphism in the onset of cervical cancer in caucasian women. Mol diag & therapy 17(4), 239-245 (2013)

  • [32]Audeh MW, Carmichael J, Penson RT, Friedlander M, Powell B, Bell-McGuinn KM, Scott C, Weitzel JN, Oaknin A, Loman N: Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. The Lancet 376(9737), 245-251 (2010)

  • [33]Barboro P, Ferrari N, Capaia M, Petretto A, Salvi S, Boccardo S, Balbi C: Expression of nuclear matrix proteins binding matrix attachment regions in prostate cancer. PARP-1: New player in tumor progression. Int J Cancer 137(7), 1574-1586 (2015)

  • [34]Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M: Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 138(2), 245-256 (2009)

  • [35]Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J, Palanisamy N, Siddiqui J, Yan W, Cao X, Mehra R, Sabolch A, Basrur V, Lonigro RJ, Yang J, Tomlins SA, Maher CA, Elenitoba-Johnson KS, Hussain M, Navone NM, Pienta KJ, Varambally S, Feng FY, Chinnaiyan AM: Mechanistic rationale for inhibition of poly(ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19(5), 664-678 (2011)

  • [36]Hassa PO, Buerki C, Lombardi C, Imhof R, Hottiger MO: Transcriptional coactivation of nuclear factor-κB-dependent gene expression by p300 is regulated by poly (ADP)-ribose polymerase-1. J Biol Chem 278(46), 45145-45153 (2003)

  • [37]Stilmann M, Hinz M, Arslan S, Zimmer A, Schreiber Vr, Scheidereit C: A nuclear poly (ADP-ribose)-dependent signalosome confers DNA damage-induced IκB kinase activation. Mol cell 36(3), 365-378 (2009)

  • [38]Murai J, Huang SY, Das BB, Renaud A, Zhang Y, Doroshow JH, Ji J, Takeda S, Pommier Y: Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res 72(21), 5588-5599 (2012)

  • [39]Murai J, Huang SY, Renaud A, Zhang Y, Ji J, Takeda S, Morris J, Teicher B, Doroshow JH, Pommier Y: Stereospecific PARP trapping by BMN 673 and comparison with olaparib and rucaparib. Mol Cancer Ther 13(2), 433-443 (2014)

  • [40]Rodrguez MI, Majuelos Melguizo J, Mart Martn, Consuegra JM, Ruiz de Almodvar M, Lpez Rivas A, Javier Oliver F: Deciphering the Insights of Poly (ADP-Ribosylation) in Tumor Progression. Med res rev 35(4), 678-697 (2015)

  • [41]Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, Friedlander M, Arun B, Loman N, Schmutzler RK: Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. The Lancet 376(9737), 235-244 (2010)

  • [42]Villamar-Cruz O, Prudnikova T, Johnson N, Chernoff J, Romero LEA: Reduced Pak1 activity sensitizes FA/BRCA-proficient breast cancer cells to PARP inhibition. Cancer Res 76(14 Supplement), 1876-1876 (2016)

  • [43]Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JPW, Bui TN, Warner S, Heymach JV, Hunt KK: AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Mol Cancer Res 0157 (2016)

  • [44]Ibrahim YH, Garc a-Garc a C, Serra V, He L, Torres-Lockhart K, Prat A, Anton P, Cozar P, Guzm¡n M, Grueso J: PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition. Cancer Discov 2(11), 1036-1047 (2012)

  • [45]Juvekar A, Burga LN, Hu H, Lunsford EP, Ibrahim YH, Balmana J, Rajendran A, Papa A, Spencer K, Lyssiotis CA, Nardella C, Pandolfi PP, Baselga J, Scully R, Asara JM, Cantley LC, Wulf GM: Combining a PI3K inhibitor with a PARP inhibitor provides an effective therapy for BRCA1-related breast cancer. Cancer Discov 2(11), 1048-1063 (2012)

  • [46]Gelmon KA, Tischkowitz M, Mackay H, Swenerton K, Robidoux A, Tonkin K, Hirte H, Huntsman D, Clemons M, Gilks B: Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study. The Lancet Oncol 12(9), 852-861 (2011)

  • [47]Kaye SB, Lubinski J, Matulonis U, Ang JE, Gourley C, Karlan BY, Amnon A, Bell-McGuinn KM, Chen L-M, Friedlander M: Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer. J Clin Oncol 30(4), 372-379 (2012)

  • [48]Ledermann J, Harter P, Gourley C, Friedlander M, Vergote I, Rustin G, Scott CL, Meier W, Shapira-Frommer R, Safra T: Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. The Lancet Oncol 15(8), 852-861 (2014)

  • [49]Penning TD, Zhu G-D, Gandhi VB, Gong J, Liu X, Shi Y, Klinghofer V, Johnson EF, Donawho CK, Frost DJ: Discovery of the poly (ADP-ribose) polymerase (PARP) inhibitor 2-((R)-2-methylpyrrolidin-2-yl)-1 H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer. J med chem 52(2), 514-523 (2008)

  • [50]Kummar S, Chen A, Ji J, Zhang Y, Reid JM, Ames M, Jia L, Weil M, Speranza G, Murgo AJ: Phase I study of PARP inhibitor ABT-888 in combination with topotecan in adults with refractory solid tumors and lymphomas. Cancer Res 71(17), 5626-5634 (2011)

  • [51]Ihnen M, Eulenburg C, Kolarova T, Qi JW, Manivong K, Chalukya M, Dering J, Anderson L, Ginther C, Meuter A: Therapeutic potential of the poly (ADP-ribose) polymerase inhibitor rucaparib for the treatment of sporadic human ovarian cancer. Mol cancer therapeutics 12(6), 1002-1015 (2013)

  • [52]Kristeleit R, LoRusso P, Patel M, Giordano H, Evans J: Phase I study of continuous oral rucaparib: analysis of patient subgroup with ovarian/peritoneal cancer. Int J Gynecol Cancer 23(8 Suppl 1), S564 (2013)

  • [53]Shapiro G, Kristeleit R, Middleton M, Burris H, Molife LR, Evans J, Wilson R, LoRusso P, Spicer J, Dieras V: ABSTRACT A218: Pharmacokinetics of orally administered rucaparib in patients with advanced solid tumors. Mol cancer therapeutics 12(11 Supplement), A218-A218 (2013)

  • [54]Shen Y, Rehman FL, Feng Y, Boshuizen J, Bajrami I, Elliott R, Wang B, Lord CJ, Post LE, Ashworth A: BMN 673, a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency. Clin Cancer Res 19(18), 5003-5015 (2013)

  • [55]Sandhu SK, Schelman WR, Wilding G, Moreno V, Baird RD, Miranda S, Hylands L, Riisnaes R, Forster M, Omlin A: The poly (ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. The Lancet Oncol 14(9), 882-892 (2013)

  • [56]Kotsopoulos IC, Kucukmetin A, Mukhopadhyay A, Lunec J, Curtin NJ: Poly (ADP-Ribose) Polymerase in Cervical Cancer Pathogenesis: Mechanism and Potential Role for PARP Inhibitors. Int J Gynecol Cancer 26(4), 763-769 (2016)

  • [57]Miyasaka A, Oda K, Ikeda Y, Wada-Hiraike O, Kashiyama T, Enomoto A, Hosoya N, Koso T, Fukuda T, Inaba K: Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells. BMC cancer 14(1), 1 (2014)

  • [58]Schiewer MJ, Goodwin JF, Han S, Brenner JC, Augello MA, Dean JL, Liu F, Planck JL, Ravindranathan P, Chinnaiyan AM: Dual roles of PARP-1 promote cancer growth and progression. Cancer Discov 2(12), 1134-1149 (2012)

  • [59]Chatterjee P, Choudhary GS, Sharma A, Singh K, Heston WD, Ciezki J, Klein EA, Almasan A: PARP inhibition sensitizes to low dose-rate radiation TMPRSS2-ERG fusion gene-expressing and PTEN-deficient prostate cancer cells. PLoS One 8(4), e60408 (2013)

  • [60]Brenner JC, Ateeq B, Li Y, Yocum AK, Cao Q, Asangani IA, Patel S, Wang X, Liang H, Yu J: Mechanistic rationale for inhibition of poly (ADP-ribose) polymerase in ETS gene fusion-positive prostate cancer. Cancer Cell 19(5), 664-678 (2011)

  • [61]Lord CJ, Ashworth A: Mechanisms of resistance to therapies targeting BRCA-mutant cancers. Nat Med 19(11), 1381-1388 (2013)

  • [62]Bouwman P, Jonkers J: Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 20(3), 540-547 (2014)

  • [63]Edwards SL, Brough R, Lord CJ, Natrajan R, Vatcheva R, Levine DA, Boyd J, Reis-Filho JS, Ashworth A: Resistance to therapy caused by intragenic deletion in BRCA2. Nature 451(7182), 1111-1115 (2008)

  • [64]Rottenberg S, Jaspers JE, Kersbergen A, van der Burg E, Nygren AO, Zander SA, Derksen PW, de Bruin M, Zevenhoven J, Lau A, Boulter R, Cranston A, O'Connor MJ, Martin NM, Borst P, Jonkers J: High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs. Proc Natl Acad Sci USA 105(44), 17079-17084 (2008)

  • [65]Jaspers JE, Kersbergen A, Boon U, Sol W, van Deemter L, Zander SA, Drost R, Wientjens E, Ji J, Aly A, Doroshow JH, Cranston A, Martin NM, Lau A, O'Connor MJ, Ganesan S, Borst P, Jonkers J, Rottenberg S: Loss of 53BP1 causes PARP inhibitor resistance in Brca1-mutated mouse mammary tumors. Cancer Discov 3(1), 68-81 (2013)

  • [66]Issaeva N, Thomas HD, Djureinovic T, Jaspers JE, Stoimenov I, Kyle S, Pedley N, Gottipati P, Zur R, Sleeth K, Chatzakos V, Mulligan EA, Lundin C, Gubanova E, Kersbergen A, Harris AL, Sharma RA, Rottenberg S, Curtin NJ, Helleday T: 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance. Cancer Res 70(15), 6268-6276 (2010)

  • [67]Yalon M, Tuval-Kochen L, Castel D, Moshe I, Mazal I, Cohen O, Avivi C, Rosenblatt K, Aviel-Ronen S, Schiby G: Overcoming Resistance of Cancer Cells to PARP-1 Inhibitors with Three Different Drug Combinations. PloS one 11(5), e0155711 (2016)

  • [68]Murai J, Feng Y, Yu GK, Ru Y, Tang SW, Shen Y, Pommier Y: Resistance to PARP inhibitors by SLFN11 inactivation can be overcome by ATR inhibition. Oncotarget (2016)

  • [69]Hong H, Jiang L, Lin Y, He C, Zhu G, Du Q, Wang X, She F, Chen Y: TNF-alpha promotes lymphangiogenesis and lymphatic metastasis of gallbladder cancer through the ERK1/2/AP-1/VEGF-D pathway. BMC Cancer 16, 240 (2016)

  • [70]Karicheva O, Rodriguez-Vargas JM, Wadier Ng, Martin-Hernandez K, Vauchelles R, Magroun N, Tissier As, Schreiber Vr, Dantzer Fo: PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis. Oncotarget 7(39), 64109-64123 (2016)

  • [71]Vyas S, Matic I, Uchima L, Rood J, Zaja R, Hay RT, Ahel I, Chang P: Family-wide analysis of poly (ADP-ribose) polymerase activity. Nat commun 5, (2016)

  • [72]Tong WM, Ohgaki H, Huang H, Granier C, Kleihues P, Wang ZQ: Null mutation of DNA strand break-binding molecule poly(ADP-ribose) polymerase causes medulloblastomas in p53(-/-) mice. Am J Pathol 162(1), 343-352 (2003)

  • [73]Ricks TK, Chiu HJ, Ison G, Kim G, McKee AE, Kluetz P, Pazdur R: Successes and Challenges of PARP Inhibitors in Cancer Therapy. Front Oncol 5, 222 (2015)

  • [74]Rajawat J, Vohra I, Mir HA, Gohel D, Begum R: Effect of oxidative stress and involvement of poly(ADP-ribose) polymerase (PARP) in Dictyostelium discoideum development. Febs J 274(21), 5611-5618 (2007)

  • [75]Wei H, Yu X: Functions of PARylation in DNA Damage Repair Pathways. Genomics Proteomics Bioinfo 14(3), 131-139 (2016)

  • [76]O'Shaughnessy J, Schwartzberg L, Danso MA, Miller KD, Rugo HS, Neubauer M, Robert N, Hellerstedt B, Saleh M, Richards P, Specht JM, Yardley DA, Carlson RW, Finn RS, Charpentier E, Garcia-Ribas I, Winer EP: Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 32(34), 3840-3847 (2014)

  • [77]Birrer MJ, Konstantinopoulos P, Penson RT, Roche M, Ambrosio A, Stallings TE, Matulonis U, Bradley CR: A phase II trial of iniparib (BSI-201) in combination with gemcitabine/carboplatin (GC) in patients with platinum-resistant recurrent ovarian cancer. J Clin Oncol 29(15_suppl), 5005 (2011)

  • [78]Dent RA, Lindeman GJ, Clemons M, Wildiers H, Chan A, McCarthy NJ, Singer CF, Lowe ES, Watkins CL, Carmichael J: Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer. Breast Cancer Res 15(5), R88 (2013)

  • [79]Tan AR, Toppmeyer D, Stein MN, Moss RA, Gounder M, Lindquist DC, Ji JJ, Chen AP, Egorin MJ, Kiesel B: Phase I trial of veliparib (ABT-888), a poly (ADP-ribose) polymerase (PARP) inhibitor, in combination with doxorubicin and cyclophosphamide in breast cancer and other solid tumors. J Clin Oncol 29(15_suppl), 3041 (2011)

  • [80]Isakoff SJ, Overmoyer B, Tung NM, Gelman RS, Giranda VL, Bernhard KM, Habin KR, Ellisen LW, Winer EP, Goss PE: A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. J of Clin Oncol 28(15_suppl), 1019 (2011)

Article Metrics

  • Information

  • Download

  • Contents

Frontiers in Bioscience-Scholar (FBS) is published by IMR Press from Volume 13 Issue 1 (2021). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with Frontiers in Bioscience.

1 Jun 2017Review

Poly(ADP-Ribose) polymerase 1: a therapeutic hope in gynecologic cancers

Jyotika Rajawat 1, Nidhi Shukla 1, Durga Prasad Mishra 1,*
Affiliation
Article Info

1 Cell Death Research Laboratory, Endocrinology Division, CSIR-Central Drug Research Institute, B.S. 10/1, Sector-10, Jankipuram Extension Lucknow, Uttar Pradesh-226031, India

*Author to whom correspondence should be addressed.

 

Abstract

The Poly(ADP-ribose) polymerase-1 (PARP1) is a multifunctional nuclear protein involved in a variety of cellular functions. Recently, its role in the onset, progression and therapy resistance of cancers in general and reproductive cancers in particular has been recognised. The PARP associated signaling is perceived to play a key role in the development, sustenance and relapse of reproductive cancers. This has led to the preclinical and clinical assessment of PARP inhibitors as targeted therapeutic agents in reproductive cancers. In the first part of this review, we have summarized the current status of PARP in the onset, progression and therapy resistance of reproductive cancers. In the second part of the review, we have discussed the translational applications of PARP inhibitors, underscoring the perceived therapeutic opportunities, bottlenecks and the utility of the ongoing clinical trials.

Keywords

  • PARP
  • Reproductive cancers
  • PARP inhibitors
  • Drug Resistance
  • Clinical Trial
  • Review

References

Cite

Share